Breaking News

One 2 One Appoints General Manager

July 17, 2013

Blair brings more than 30 years of experience

Karen Blair has joined Hospira Inc. as general manager to lead One 2 One™, Hospira’s contract development and manufacturing services business. Mrs. Blair will be responsible for overall P&L accountability, sales, marketing, business development, and customer relationship management. She will also lead the One 2 One™ team, which includes operations, R&D, program management and other functions, to ensure the overall success of One 2 One™ business.
Mrs. Blair brings more than 30 years of experience across a broad spectrum of pharmaceutical marketing and general management roles as well as in contract manufacturing. She spent most of her career with Baxter Healthcare in roles of increasing responsibility in marketing, sales and general management, including holding the position of vice president / general manager of Baxter BioPharma Solutions. During her time at Baxter, she drove substantial growth of the contract manufacturing services business and promoted a culture of customer service excellence.
Karen Blair said, “I am very excited about the opportunity to contribute to the success of Hospira One 2 One™. For quite some time I had been observing One 2 One™ as one of the major competitors and now I will be helping to shape its future. The strength of this business, expertise in parenteral product manufacturing, is truly substantial. One 2 One™ has more than 20 years of experience in addressing customer challenges and developing best practices in small molecule and biologics fill/finish technology, lyophilization, and global commercialization. I envision a great future for One 2 One™ as a preferred partner for parenteral drug manufacturing.”

Related Contract Manufacturing:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks